转移性-话题@MedSci

#转移性#

975篇内容 | 3477人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1386656, encodeId=b24f1386656a7, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Nat Commun：临床试验证实，粪便微生物移植可治疗转移性肾癌患者腹泻, objectType=article, longId=200030, objectId=4cbf200030b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4cbf200030b7, replyNumber=0, likeNumber=128, createdTime=2020-08-31, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4cbf200030b7, moduleTitle=Nat Commun：临床试验证实，粪便微生物移植可治疗转移性肾癌患者腹泻, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4cbf200030b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386655, encodeId=699f138665584, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Eur Urol：局部晚期和转移性尿道癌中成纤维细胞生长因子受体3的变异状态与对铂化疗敏感性的差异相关, objectType=article, longId=199985, objectId=72b119998516, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=72b119998516, replyNumber=0, likeNumber=18, createdTime=2020-08-29, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=72b119998516, moduleTitle=Eur Urol：局部晚期和转移性尿道癌中成纤维细胞生长因子受体3的变异状态与对铂化疗敏感性的差异相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=72b119998516)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386654, encodeId=b159138665467, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=JTO：信迪利单抗联合培美曲塞和铂类作为局部晚期或转移性非鳞状NSCLC一线治疗的有效性和安全性(ORIENT-11), objectType=article, longId=199903, objectId=f051199903bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f051199903bb, replyNumber=0, likeNumber=70, createdTime=2020-08-26, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f051199903bb, moduleTitle=JTO：信迪利单抗联合培美曲塞和铂类作为局部晚期或转移性非鳞状NSCLC一线治疗的有效性和安全性(ORIENT-11), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f051199903bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386653, encodeId=e4b91386653ef, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=康方生物抗PD-1/CTLA-4双特异性抗体治疗转移性宫颈癌，获得FDA快速指定, objectType=article, longId=199753, objectId=c938199e53cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c938199e53cd, replyNumber=0, likeNumber=74, createdTime=2020-08-22, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c938199e53cd, moduleTitle=康方生物抗PD-1/CTLA-4双特异性抗体治疗转移性宫颈癌，获得FDA快速指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c938199e53cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386652, encodeId=d2ef138665266, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=J Clin Oncol：转移性鳞状非小细胞肺癌患者中使用卡铂-紫杉醇联合培博利珠单抗可改善患者的生活质量, objectType=article, longId=199699, objectId=d1b8199699d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d1b8199699d0, replyNumber=0, likeNumber=62, createdTime=2020-08-21, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d1b8199699d0, moduleTitle=J Clin Oncol：转移性鳞状非小细胞肺癌患者中使用卡铂-紫杉醇联合培博利珠单抗可改善患者的生活质量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d1b8199699d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386651, encodeId=27c3138665131, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Annals of Oncology：T-DM1在HER2阳性转移性乳腺癌和脑转移乳腺癌患者中的疗效与安全性, objectType=article, longId=199369, objectId=112e19936941, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=112e19936941, replyNumber=0, likeNumber=68, createdTime=2020-08-15, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=112e19936941, moduleTitle=Annals of Oncology：T-DM1在HER2阳性转移性乳腺癌和脑转移乳腺癌患者中的疗效与安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=112e19936941)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386650, encodeId=2b80138665082, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=TUKYSA（tucatinib）在澳大利亚获得批准，用于治疗转移性HER2阳性乳腺癌, objectType=article, longId=199343, objectId=af9d1993432d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af9d1993432d, replyNumber=0, likeNumber=66, createdTime=2020-08-14, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af9d1993432d, moduleTitle=TUKYSA（tucatinib）在澳大利亚获得批准，用于治疗转移性HER2阳性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af9d1993432d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386649, encodeId=c3661386649b2, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Lancet oncol：奥拉帕利联合Durvalumab治疗BRCA突变的转移性乳腺癌, objectType=article, longId=199142, objectId=daaa19914221, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=daaa19914221, replyNumber=0, likeNumber=57, createdTime=2020-08-12, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=daaa19914221, moduleTitle=Lancet oncol：奥拉帕利联合Durvalumab治疗BRCA突变的转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=daaa19914221)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386648, encodeId=97121386648fe, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Clin Cancer Res：阿帕鲁胺联合醋酸阿比特龙和泼尼松治疗转移性去势抵抗性前列腺癌！, objectType=article, longId=198652, objectId=f4a019865234, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4a019865234, replyNumber=0, likeNumber=88, createdTime=2020-08-05, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4a019865234, moduleTitle=Clin Cancer Res：阿帕鲁胺联合醋酸阿比特龙和泼尼松治疗转移性去势抵抗性前列腺癌！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f4a019865234)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386647, encodeId=da1e138664e4b, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=LONSURF将在中国上市，用于治疗转移性结直肠癌, objectType=article, longId=198320, objectId=4f79198320c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f79198320c7, replyNumber=0, likeNumber=54, createdTime=2020-07-31, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f79198320c7, moduleTitle=LONSURF将在中国上市，用于治疗转移性结直肠癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4f79198320c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386646, encodeId=82381386646ab, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=NEJM：转移性透明细胞肉瘤-病例报道, objectType=article, longId=197957, objectId=a8d719e9573c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8d719e9573c, replyNumber=0, likeNumber=63, createdTime=2020-07-25, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8d719e9573c, moduleTitle=NEJM：转移性透明细胞肉瘤-病例报道, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8d719e9573c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386645, encodeId=373b13866458c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=NAT COMMUN：HER2 CAR T治疗转移性横纹肌肉瘤患儿后的肿瘤反应和内源性免疫反应性 , objectType=article, longId=197630, objectId=9bc519e630b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9bc519e630b6, replyNumber=0, likeNumber=77, createdTime=2020-07-18, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9bc519e630b6, moduleTitle=NAT COMMUN：HER2 CAR T治疗转移性横纹肌肉瘤患儿后的肿瘤反应和内源性免疫反应性 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9bc519e630b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386644, encodeId=74ca13866449d, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Cancer：血管内皮生长因子治疗转移性甲状腺癌的效果, objectType=article, longId=197473, objectId=3a6e19e473b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a6e19e473b7, replyNumber=0, likeNumber=78, createdTime=2020-07-15, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a6e19e473b7, moduleTitle=Cancer：血管内皮生长因子治疗转移性甲状腺癌的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3a6e19e473b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386643, encodeId=b8a51386643c3, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Lancet oncol：卡博替尼治疗铂耐药的转移性尿路上皮癌, objectType=article, longId=197427, objectId=6caa19e42798, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6caa19e42798, replyNumber=0, likeNumber=68, createdTime=2020-07-14, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6caa19e42798, moduleTitle=Lancet oncol：卡博替尼治疗铂耐药的转移性尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6caa19e42798)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386642, encodeId=f8ee138664206, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=抗体药物偶联物DS-1062研究范围被扩大，治疗晚期或转移性三阴性乳腺癌, objectType=article, longId=196920, objectId=36881969209a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36881969209a, replyNumber=0, likeNumber=93, createdTime=2020-07-04, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36881969209a, moduleTitle=抗体药物偶联物DS-1062研究范围被扩大，治疗晚期或转移性三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36881969209a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386641, encodeId=75571386641bf, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=PD-L1单抗Bavencio，获得FDA批准用于晚期或转移性尿路上皮癌患者的维持治疗, objectType=article, longId=196892, objectId=c2de19689221, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2de19689221, replyNumber=0, likeNumber=52, createdTime=2020-07-03, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2de19689221, moduleTitle=PD-L1单抗Bavencio，获得FDA批准用于晚期或转移性尿路上皮癌患者的维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2de19689221)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386640, encodeId=0a21138664012, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=CheckMate-870结果公布：欧狄沃240毫克固定剂量30分钟输注在以中国人群为主的经治晚期或转移性NSCLC患者中安全可靠, objectType=article, longId=196839, objectId=69e81968399f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69e81968399f, replyNumber=0, likeNumber=80, createdTime=2020-07-02, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69e81968399f, moduleTitle=CheckMate-870结果公布：欧狄沃240毫克固定剂量30分钟输注在以中国人群为主的经治晚期或转移性NSCLC患者中安全可靠, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=69e81968399f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386639, encodeId=19e213866391e, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=FDA批准Keytruda作为MSI-H / dMMR转移性结直肠癌的一线疗法, objectType=article, longId=196815, objectId=70ef1968157f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=70ef1968157f, replyNumber=0, likeNumber=114, createdTime=2020-07-02, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=70ef1968157f, moduleTitle=FDA批准Keytruda作为MSI-H / dMMR转移性结直肠癌的一线疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=70ef1968157f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386638, encodeId=707613866383c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Tisotumab Vedotin治疗复发或转移性宫颈癌：II期临床试验取得阳性结果, objectType=article, longId=196814, objectId=693e19681493, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=693e19681493, replyNumber=0, likeNumber=83, createdTime=2020-07-02, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=693e19681493, moduleTitle=Tisotumab Vedotin治疗复发或转移性宫颈癌：II期临床试验取得阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=693e19681493)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386637, encodeId=a05b138663ed1, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=PD-1单抗KEYTRUDA：首次获FDA批准治疗复发或转移性皮肤鳞状细胞癌, objectType=article, longId=196530, objectId=ecbe1965305c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ecbe1965305c, replyNumber=0, likeNumber=89, createdTime=2020-06-27, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ecbe1965305c, moduleTitle=PD-1单抗KEYTRUDA：首次获FDA批准治疗复发或转移性皮肤鳞状细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ecbe1965305c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

转移性

2020-05-29

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Nat Commun：临床试验证实，粪便微生物移植可治疗转移性肾癌患者腹泻

2020-08-31

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Eur Urol：局部晚期和转移性尿道癌中成纤维细胞生长因子受体3的变异状态与对铂化疗敏感性的差异相关

2020-08-29

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

JTO：信迪利单抗联合培美曲塞和铂类作为局部晚期或转移性非鳞状NSCLC一线治疗的有效性和安全性(ORIENT-11)

2020-08-26

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

康方生物抗PD-1/CTLA-4双特异性抗体治疗转移性宫颈癌，获得FDA快速指定

2020-08-22

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

J Clin Oncol：转移性鳞状非小细胞肺癌患者中使用卡铂-紫杉醇联合培博利珠单抗可改善患者的生活质量

2020-08-21

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Annals of Oncology：T-DM1在HER2阳性转移性乳腺癌和脑转移乳腺癌患者中的疗效与安全性

2020-08-15

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

TUKYSA（tucatinib）在澳大利亚获得批准，用于治疗转移性HER2阳性乳腺癌

2020-08-14

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Lancet oncol：奥拉帕利联合Durvalumab治疗BRCA突变的转移性乳腺癌

2020-08-12

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Clin Cancer Res：阿帕鲁胺联合醋酸阿比特龙和泼尼松治疗转移性去势抵抗性前列腺癌！

2020-08-05

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

LONSURF将在中国上市，用于治疗转移性结直肠癌

2020-07-31

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

NEJM：转移性透明细胞肉瘤-病例报道

2020-07-25

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

NAT COMMUN：HER2 CAR T治疗转移性横纹肌肉瘤患儿后的肿瘤反应和内源性免疫反应性

2020-07-18

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Cancer：血管内皮生长因子治疗转移性甲状腺癌的效果

2020-07-15

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Lancet oncol：卡博替尼治疗铂耐药的转移性尿路上皮癌

2020-07-14

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

抗体药物偶联物DS-1062研究范围被扩大，治疗晚期或转移性三阴性乳腺癌

2020-07-04

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

PD-L1单抗Bavencio，获得FDA批准用于晚期或转移性尿路上皮癌患者的维持治疗

2020-07-03

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

CheckMate-870结果公布：欧狄沃240毫克固定剂量30分钟输注在以中国人群为主的经治晚期或转移性NSCLC患者中安全可靠

2020-07-02

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

FDA批准Keytruda作为MSI-H / dMMR转移性结直肠癌的一线疗法

2020-07-02

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Tisotumab Vedotin治疗复发或转移性宫颈癌：II期临床试验取得阳性结果

2020-07-02

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

PD-1单抗KEYTRUDA：首次获FDA批准治疗复发或转移性皮肤鳞状细胞癌

2020-06-27

科室
- - 订阅+
  - 更多科室
工具
服务